FDA
-
-
-
-
-
-
-
Genentech to Present New Data From Its Broad and Innovative Hematology Portfolio at ASH 2025
-
-
-
-
-
-
-
Roche receives FDA approval for first companion diagnostic to identify patients with biliary tract cancer eligible for HER2-targeted treatment with ZIIHERA
-
-
-
-
-
-
-
Roche launches next-generation qPCR system to advance clinical needs in molecular diagnostics and address public health challenges
-
-
-
-
-
-
-
Genentech to Present Data at ASH 2022 Showcasing Strength of Hematology Portfolio and Expanding Into New Areas to Address More Patient Needs
-
-
-
-
-
-
-
Interim Data From Phase III HAVEN 6 Study Demonstrate Favorable Safety and Efficacy Profile of Genentech’s Hemlibra (emicizumab-kxwh) in People With Moderate or Mild Hemophilia A
-
-
-
-
-
-
-
Roche receives FDA approval for VENTANA ALK (D5F3) CDx Assay to identify lung cancer patients eligible for targeted treatment with LORBRENA (lorlatinib)
-
-
-
-
-
-
-
Genentech’s Phase III EMPACTA Study Showed Actemra Reduced the Likelihood of Needing Mechanical Ventilation in Hospitalized Patients With COVID-19 Associated Pneumonia
-
331,394 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

